Biopharmaceutical company ImaRx Therapeutics Inc., of Tucson, Ariz., and Royal Philips Electronics today announced they have joined together to research a potential new treatment for acute ischemic stroke, using ImaRx’s proprietary microbubble system and Philips ultrasound technology.
The partnership will particularly focus on determining the optimal parameters of Philips ultrasound product as part of ImaRx’s SonoLysis program, which is designed to break up blood clots and restore blood flow to oxygen-deprived tissues.
Under terms of the deal, Philips’ Medical Systems division will provide ultrasound devices and technical services to ImaRx during laboratory and preclinical studies. The agreement also includes a mutual exclusivity clause during the term of the collaboration.
Once research has ended, Philips and ImaRx will have an exclusive negotiation period to discuss future development and commercialization.
